Sanofi Bets Big On IO With Synthorx Buy
Expects Interleukin-2 To Be Foundation Of Future IO-IO Combos
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
You may also be interested in...
Sanofi R&D head John Reed says company has kept 95% of patients on its nearly 400 clinical trials and started 59 studies. Company has also stepped up collaborations and closed acquisitions, integrating employees remotely.
Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.